Congenital Heart Disease Market Report 2025 (Global Edition)

Global Congenital Heart Disease Market Report 2025 Market Size Split by Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Others), by Diagnosis (Electrocardiogram, Chest X-ray, Echo...

Congenital Heart Disease Market Report Description

We have various report editions of Congenital Heart Disease Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Congenital Heart Disease Market Insights Video

Competitive Landscape of the Congenital Heart Disease Market

The congenital heart disease (CHD) market is dominated by a broad set of businesses, including huge multinational corporations, specialized medical equipment manufacturers, and rising biotech enterprises. Leading companies are actively focusing on innovation and technological advancements to enhance treatment outcomes, which include developing minimally invasive surgical techniques, advanced diagnostic tools, and novel therapeutic approaches. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their product portfolios and global market reach.

In May 2024, Novartis AG introduced Entresto Granular Tablets, a new formulation of its heart failure medication designed exclusively for juvenile patients. This is the first ARNI therapeutic option available for children with persistent heart failure. The medicine has been licensed for use in children with persistent heart failure, which is frequently caused by congenital heart disease or cardiomyopathy. (Source: https://www.otsuka.co.jp/en/company/newsreleases/2024/20240522_1.html) In June 2021, Abbott, the global healthcare firm, released its Amplatzer Piccolo™ Occluder in India, the world's first medical device that can be implanted in the youngest babies (weighing as low as 700 gms) using a minimally invasive method to treat patent ductus arteriosus or PDA. PDA is a potentially fatal hole between two blood arteries flowing from the heart and is one of the most frequent congenital heart abnormalities seen in premature babies. The Amplatzer Piccolo, a device smaller than a little pea, now gives hope to premature infants and newborns who require corrective treatment, may be non-responsive to medicine, and are at high risk of undergoing corrective surgery. (Source: https://www.abbott.in/media-center/press-releases/abbott-launches-new-device-in-india-for-treatment-of-premature-babies-and-newborns-with-a-life-threatening-opening-in-their-hearts.html)

Top Companies Market Share in Congenital Heart Disease Industry: (In no particular order of Rank)

• Medtronic plc (Ireland)
• Abbott Laboratories (U.S.)
• Boston Scientific Corporation (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• Terumo Corporation (Japan)
• Surgical Science (Sweden)
• LivaNova PLC (U.K.)
• AtriCure
• Inc. (U.S.)
• Philips Healthcare (Netherlands)
• Cordis Corporation (U.S.)
• Biotronik SE & Co. KG (Germany)
• Merit Medical Systems
• Inc. (U.S.)
• Stryker Corporation (U.S.)
• Siemens Healthineers (Germany)
• GE Healthcare (U.S.)
• Asahi Intecc Co.
• Ltd. (Japan)
• Nuvectra Corporation (U.S.)
• MediCure Inc. (Canada)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Congenital Heart Disease Market

Which Region Dominates the Congenital Heart Disease Market in 2024?

According to Cognitive Market Research, North America holds a majority share in the global congenital heart disease market revenue primarily due to its highly advanced healthcare infrastructure, higher prevalence of congenital heart defects, and heavy investment in medical research and technology. This region has leading hospitals and specialized pediatric cardiology centers equipped with modern diagnostic and therapeutic tools, enabling early detection and effective treatment of congenital heart disease. The strong presence of major medical device manufacturers and pharmaceutical companies in the U.S. fosters innovation and rapid deployment of new therapies and technologies.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region stands out as the fastest-growing market for congenital heart disease. Rapid urbanization and economic development have led to increased healthcare spending and improved access to medical services across countries such as China, India, and Japan. The rising regional prevalence of congenital heart defects, coupled with enhanced awareness and early diagnosis initiatives, has heightened the market need for effective treatment options. The region is also witnessing a growing trend in pediatric cardiology, with more healthcare providers focusing on innovative treatments and surgical interventions.

The current report Scope analyzes Congenital Heart Disease Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Congenital Heart Disease Market Analysis

According to Cognitive Market Research, the global congenital heart disease market size was estimated at USD 4325.2 million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1730.1 million in 2024 and will climb at a CAGR of 7.9% from 2024 to 2031.

• According to Cognitive Market Research, the U.S. had a major share in the congenital heart disease market with a market size of USD 1365 million in 2024 and is projected to grow at a CAGR of 7.7% in the forecast period. The elevated prevalence of congenital heart defects among newborns and improvements in surgical techniques are propelling the U.S. market demand for specialized pediatric cardiac care.
• The Canada congenital heart disease market had a market share of USD 207.6 million in 2024 and is likely to scale at a CAGR of 8.7% in the forecasted period. The Canadian market for congenital heart disease is mainly supported by a robust healthcare system that supports R&D projects in cardiology.
• The Mexico congenital heart disease market is likely to experience growth at a CAGR of 8.4% within the forecast timeframe, with a market size of USD 157.4 million in 2024.

Europe Congenital Heart Disease Market Analysis

According to Cognitive Market Research, the global congenital heart disease market size was estimated at USD 4325.2 million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1297.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.

• The U.K. congenital heart disease market had a market share of USD 218 million in 2024 and is likely to broaden at a CAGR of 9% within the predicted timeframe. In the U.K., the growth of the congenital heart disease market is facilitated by the National Health Service (NHS) focused on comprehensive cardiac care programs.
• The France congenital heart disease market is anticipated to develop at a 7.4% CAGR throughout the projected time frame, reaching USD 119.4 million in 2024.
• According to Cognitive Market Research, the German congenital heart disease market size was valued at USD 256.9 million in 2024 and is projected to evolve at a CAGR of 8.4% through the estimated period. This country primarily benefits from a high level of healthcare spending and strong collaboration between the public and private sectors, leading to improved treatment modalities and patient outcomes.
• The Italy congenital heart disease market is projected to witness growth at a CAGR of 7.6% over the forecast time frame, with a market value size of USD 111.6 million in 2024.
• The Russian congenital heart disease market is likely to witness growth at a CAGR of 7.2% in the projected period, with a market value size of USD 201.1 million in 2024.
• The Spain congenital heart disease market is predicted to witness growth at a CAGR of 7.3% during the assessment period, with a market size of USD 106.4 million in 2024.
• The Luxembourg congenital heart disease market is projected to witness growth at a CAGR of 8.3% during the research time frame, with a market size of USD 40.2 million in 2024.
• The Portugal congenital heart disease market is anticipated to witness growth at a CAGR of 8% during the forecasting time frame, with a market size of USD 27.2 million in 2024.
• The Greece congenital heart disease market is predicted to witness growth at a CAGR of 8.5% over the assessment period, with a market size of USD 15.6 million in 2024.
• The Rest of the European congenital heart disease market is estimated to witness growth at a CAGR of 6.9% in the forecast period, with a market size of USD 201.1 million in 2024.

Asia Pacific Congenital Heart Disease Market Analysis

According to Cognitive Market Research, the global congenital heart disease market size was estimated at USD 4325.2 million, out of which Asia Pacific held the market share of nearly 23% of the global revenue with a market size of USD 994.8 million in 2024 and will emerge at a CAGR of 11.7% from 2024 to 2031.

• According to Cognitive Market Research, the China congenital heart disease market size was valued at USD 447.7 million in 2024 and is likely to evolve at a CAGR of 11.2% in the forecasted period. In China, rapid urbanization and improvements in healthcare access are major growth factors for the congenital heart disease market.
• The Japan congenital heart disease market is expected to flourish at a 10.2% CAGR throughout the projected time frame, reaching a market value of USD 137.3 million in 2024.
• The India congenital heart disease market had a market share of USD 119.4 million in 2024 and is likely to climb at a CAGR of 13.5% within the anticipated timeframe. Increased advancements in healthcare technology and the growing private healthcare sector are enhancing treatment options and accessibility in the Indian market.
• The South Korean congenital heart disease market is predicted to widen at a CAGR of 10.8% over the forecasted period, with a market size of USD 99.5 million in 2024.
• The Australian congenital heart disease market is likely to witness growth at a CAGR of 11.4% throughout the predicted timeframe, with a market size of USD 51.7 million in 2024.
• The Southeast Asia congenital heart disease market is anticipated to experience growth at a CAGR of 12.7% in the forecast timeframe, with a market size of USD 68.6 million in 2024.
• The Rest of Asia Pacific congenital heart disease market is anticipated to see growth at a CAGR of 11.5% in the forecast period, with a market size of USD 70.6 million in 2024.

South America Congenital Heart Disease Market Analysis

According to Cognitive Market Research, the global congenital heart disease market size was estimated at USD 4325.2 million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 216.3 million in 2024 and will climb at a CAGR of 9.1% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil congenital heart disease market size was valued at USD 92.6 million in 2024 and is estimated to develop at a CAGR of 9.7% throughout the projection period. The rise in diagnostic facilities and surgical interventions for congenital heart defects, owing to both public and private healthcare sectors, supports the overall expansion of the Brazilian market.
• Argentina congenital heart disease market had a market share of USD 36.3 million in 2024 and is likely to climb at a CAGR of 10% within the forecasted period. In Argentina, the congenital heart disease market growth is supported by enhanced healthcare policies aimed at improving access to cardiac care for children.
• Colombia congenital heart disease market is projected to witness growth at a CAGR of 8.9% within the forecast timeframe, with a market size of USD 19.2 million in 2024.
• Peru congenital heart disease market is projected to witness growth at a CAGR of 9.3% throughout the anticipated period, with a market size of USD 17.7 million in 2024.
• Chile congenital heart disease market is likely to observe growth at a CAGR of 9.4% within the estimated time frame, with a market size of USD 15.6 million in 2024.
• The Rest of Latin American congenital heart disease market is estimated to see growth at a CAGR of 8.2% in the forecast period, with a market size of USD 34.8 million in 2024.

Middle East Congenital Heart Disease Market Analysis

According to Cognitive Market Research, the global congenital heart disease market size was estimated at USD 4325.2 million, out of which the Middle East & Africa held the major market share of around 2% of the global revenue with a market size of USD 86.5 million in 2024 and will scale at a CAGR of 9.4% from 2024 to 2031.

• The GCC countries congenital heart disease market is anticipated to flourish at a CAGR of 10.2% during the forecast period, reaching USD 37 million in 2024. The rising incidence of congenital heart defects among infants, coupled with improved access to specialized healthcare services, contributes to the market's growth in these GCC countries.
• The Egypt congenital heart disease market is expected to develop at a 9.7% CAGR over the forecast period, reaching USD 9.1 million in 2024.
• The South Africa congenital heart disease market is predicted to widen at a CAGR of 10.4% within the forecast timeframe, with a market size of USD 13.7 million in 2024. The establishment of specialized cardiac centers and increased public awareness of congenital heart diseases are the main factors supporting market expansion in this country.
• The Turkey congenital heart disease market is projected to witness growth at a CAGR of 8.9% in the forecasted period, with a market size of USD 7.4 million in 2024.
• The Nigeria congenital heart disease market is expected to increase at a CAGR of 8.5% over the projected time frame, with a market size of USD 9.1 million by 2024.
• The Rest of the MEA congenital heart disease market is predicted to rise at a CAGR of 8.4% in the forecast period, with a market size of USD 10.2 million in 2024.

Congenital Heart Disease Market Analysis

Congenital Heart Disease Market Type Segment Analysis

According to Cognitive Market Research, heart valve defects represent a leading category within the congenital heart disease market, as they encompass various abnormalities in the heart's valves, which can impede proper blood flow. These defects often require intervention through surgical repair or replacement to ensure optimal heart function. The prevalence of heart valve defects among congenital heart conditions is substantial, which makes it a focal point for healthcare providers and medical device manufacturers.

Blood vessel defects, characterized by abnormalities in the arteries or veins connected to the heart, represent the fastest-growing segment in the congenital heart disease market. These defects can lead to serious complications, including inadequate blood circulation and increased strain on the heart. The growing prevalence of blood vessel defects can be attributed to a combination of factors, including genetic predispositions and environmental influences.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Congenital Heart Disease Industry. Request a Free Sample PDF!

Congenital Heart Disease Market Diagnosis Segment Analysis

According to Cognitive Market Research, the electrocardiogram (ECG or EKG) is the dominant segment in the congenital heart disease market for diagnosis. This widely used diagnostic tool measures the electrical activity of the heart and helps identify various heart conditions, including congenital heart defects. Its dominance is also attributed to the growing awareness of congenital heart diseases and the importance of early diagnosis in improving patient outcomes.

The echocardiogram is a rapidly developing category in the congenital heart disease diagnosis market. This non-invasive imaging technique uses ultrasound waves to create real-time images of the heart structure and function, providing crucial insights into congenital abnormalities. The introduction of portable echocardiography devices and improvements in image quality and interpretation software are expanding the utility of echocardiograms in various clinical settings.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Congenital Heart Disease Treatment Segment Analysis

Congenital Heart Disease Market Treatment Segment Analysis

According to Cognitive Market Research, medications play a key role in the management of congenital heart disease, holding the majority share in the treatment segment. These pharmaceutical interventions are vital for controlling symptoms, managing associated conditions, and preventing complications in patients with congenital heart defects. The growth of this segment is supported by ongoing R&D efforts to create more effective and targeted therapies, along with increasing awareness among healthcare professionals and patients about the importance of medication adherence in managing congenital heart disease.

Surgery represents the highest growing segment in the congenital heart disease market treatment. Surgical interventions are often necessary for correcting structural heart defects, ensuring proper blood flow, and improving overall cardiac function. Innovative technologies, including robotic-assisted surgery and enhanced imaging techniques, have improved surgical outcomes and reduced recovery times for patients. Besides, the rising success rates of surgeries for complex congenital heart defects are further contributing to a growing patient population seeking surgical solutions.

• Medications
• Surgery
• Others

Congenital Heart Disease Route of Administration Segment Analysis

Congenital Heart Disease Market Route of Administration Segment Analysis

According to Cognitive Market Research, the oral route of administration is the dominant segment in the congenital heart disease market. Medications administered orally are preferred for their convenience, ease of use, and patient compliance. Oral formulations, such as tablets and liquid solutions, are commonly prescribed to manage symptoms and control the progression of congenital heart disease. The ability to administer medications at home without the need for professional assistance makes oral treatments especially appealing for pediatric patients and their families.

The parenteral route of administration is a rapidly growing category in the congenital heart disease market. This method, which includes injections and infusions, is essential for delivering medications that require immediate action or are not effectively absorbed through the gastrointestinal tract. Parenteral administration is often used in acute settings or for patients with severe symptoms who need rapid therapeutic effects. Recent advancements in biotechnology and the development of novel injectable therapies are expanding the scope of parenteral treatments available for congenital heart disease.

• Oral
• Parenteral
• Others

Congenital Heart Disease End Users Segment Analysis

Congenital Heart Disease Market End Users Segment Analysis

According to Cognitive Market Research, hospitals represent the leading category in the congenital heart disease market's end users segment. They serve as primary healthcare facilities for diagnosing and treating congenital heart defects, offering comprehensive services that include advanced imaging, surgical interventions, and intensive care. The presence of advanced technologies and multidisciplinary care within hospitals ensures that patients receive timely and effective treatment.

Specialty clinics are the fastest developing segment in the congenital heart disease market. These clinics focus exclusively on diagnosing and treating heart conditions, offering personalized care tailored to the specific needs of patients with congenital heart defects. Specialty clinics often provide services such as routine check-ups, ongoing management, and follow-up care, which make them essential for long-term patient health.

• Hospitals
• Specialty Clinics
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion